Acute Myelogenous Leukemia in Childhood

1 Introduction.- 1.1 Development of AML Therapy in Children.- 1.2 Prognostic Parameters in AML.- 1.3 Objectives of the Analysis.- 2 Patients and Therapy.- 2.1 Patient Eligibility.- 2.2 Therapy Schedule for Study AML-BFM-78.- 2.3 Therapy Schedule for Study AML-BFM-83.- 3 Definitions and Methods.- 3.1 Definitions.- 3.2 Diagnostic Methods.- 3.3 Statistical Methods.- 4 Results.- 4.1 Analysis of Pretherapeutic Patient Data.- 4.2 Correlation of Initial Parameters Including Kinetics of Blast Cell Reduction.- 4.3 Outcome.- 4.4 Results by Morphologic Subtypes.- 4.6 Early Death Due to Hemorrhage and/or Leukostasis and Other Complications.- 4.7 Analysis of the Implementation of Therapy in AML-BFM-83 Study.- 4.8 Toxicity During the Individual Therapy Phases of AML-BFM-83 Study.- 5 Discussion.- 5.1 Clinical and Morphologic Characteristics of Childhood AML.- 5.1.1 Epidemiological Factors.- 5.1.2 Clinical Data.- 5.2 Characterization of the FAB Types M1-M7 in Children by Pretherapeutic Parameters.- 5.3 Evaluation of the Relationship Between Pretherapeutic Parameters.- 5.4 Prognostic Relevance of Pretherapeutic Parameters and Response Kinetics: Definition of Prognostic Groups.- 5.5 Influence of Therapy on the Prognostic Relevance of Pretherapeutic Parameters: Evaluating the Introduction of ADE Induction Therapy in AML-BFM-83 Study.- 5.6 Early Death Due to Hemorrhage and/or Leukostasis and Other Complications: Consequences for Initial Therapy.- 5.7 Relationship Between Implementation of Therapy, Complications, and Course.- 5.8 Perspectives for Future Prognosis-Adapted Therapy Strategies.- 6 Summary.- 7 References.- 8 Appendix.- 9 Subject Index.